Zolmitriptan, a selective 5-HT(1B/D) agonist was developed for the acute 
treatment of migraine. Dose-finding studies show a clearly defined dose response 
curve for the oral formulation with onset of efficacy demonstrated within 45 min 
of dosing. Clinical trials support its efficacy in all types of migraine, with 
excellent safety and tolerability in those patients for whom zolmitriptan is not 
contraindicated. Future developments, including new formulations, will provide 
patients with a greater choice of treatment.